In vitro and in vivo characterization of temoporfin-loaded PEGylated PLGA nanoparticles for use in photodynamic therapy

Nanomedicine

Volumn 7, Issue 5, 2012, Pages 663-677

  Rojnik, Matija ^a   Kocbek, Petra ^a   Moret, Francesca ^b   Compagnin, Chiara ^b   Celotti, Lucia ^b   Bovis, Melissa J ^c   Woodhams, Josephine H ^c   MacRobert, Alexander J ^c   Scheglmann, Dietrich ^d   Helfrich, Wijnand ^e   Verkaik, Marco J ^e   Papini, Emanuele ^b   Reddi, Elena ^b   Kos, Janko ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Research and Development Biolitec AG   (Germany)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

cytotoxicity; meta tetra(hydroxyphenyl)chlorin; nanoparticles; PEGylation; photodynamic therapy; poly (d,l lactide co glycolide)

Indexed keywords

MACROGOL; MONOMER; NANOPARTICLE; TEMOPORFIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER THERAPY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LACTIC ACID; MESOPORPHYRINS; MICE; MICE, NUDE; NANOPARTICLES; PHOTOCHEMOTHERAPY; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID;

EID: 84861632839     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.130     Document Type: Article

References (40)

1. Jori G. Tumour photosensitizers: approaches to enhance the selectivity and effciency of photodynamic therapy. J. Photochem. Photobiol. B. 36(2), 87-93 (1996). (Pubitemid 27011249)
2. Levy JG. Photodynamic therapy. Trends Biotechnol. 13(1), 14-18 (1995).
3. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat. Res. 150(5 Suppl.), 146-156 (1998).
4. Dougherty TJ, Gomer CJ, Henderson BW et al. Photodynamic therapy. J. Natl Cancer Inst. 90(12), 889-905 (1998). (Pubitemid 28304157)
5. Ball DJ, Vernon DI, Brown SB. The high photoactivity of m-THPC in photodynamic therapy. Unusually strong retention of m-THPC by RIF-1 cells in culture. Photochem. Photobiol. 69(3), 360-363 (1999). (Pubitemid 129554864)
6. Ris HB, Altermatt HJ, Inderbitzi R et al. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br. J. Cancer 64(6), 1116-1120 (1991).
7. Tan IB, Dolivet G, Ceruse P, Poorten V V, Roest G, Rauschning W. Temoporfn-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study. Head Neck 32(12), 1597-1604 (2010).
8. Hopper C, Kübler A, Lewis H, Tan IB, Putnam G. Temoporfn-mediated photodynamic therapy for early oral squamous cell carcinoma. Int. J. Cancer 111(1), 138-146 (2004). (Pubitemid 38859295)
9. Nathan TR, Whitelaw DE, Chang SC et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a Phase I study. J. Urol. 168(4), 1427-1432 (2002). (Pubitemid 35034139)
10. Sibani SA, McCarron PA, Woolfson AD, Donnelly R F. Photosensitiser delivery for photodynamic therapy. Part 2: systemic carrier platforms. Exp. Opin. Drug Deliv. 5(11), 1241-1254 (2008).
11. Cegnar M, Kristl J, Kos J. Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Exp. Opin. Biol. Ther. 5(12), 1557-1569 (2005). (Pubitemid 41771847)
12. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 59(8), 718-728 (2007). (Pubitemid 47320811)
13. Lü JM, Wang X, Marin-Muller C et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Exp. Rev. Mol. Diagn. 9(4), 325-341 (2009).
14. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv. Drug Deliv. Rev. 60(15), 1627-1637 (2008).
15. Hu Z, Pan Y, Wang J, Chen J, Li J, Ren L. Meso-tetra (carboxyphenyl) porphyrin (TCPP) nanoparticles were internalized by SW480 cells by a clathrin-mediated endocytosis pathway to induce high photocytotoxicity. Biomed. Pharmacother. 63(2), 155-164 (2009).
16. Konan-Kouakou YN, Boch R, Gurny R, Allémann E. In vitro and in vivo activities of verteporfn-loaded nanoparticles. J. Control Release 103(1), 83-91 (2005). (Pubitemid 40248563)
17. Vargas A, Pegaz B, Debefve E et al. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. Int. J. Pharm. 286(1-2), 131-145 (2004). (Pubitemid 39410481)
18. Owens DE, Peppas. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006). (Pubitemid 41773257)
19. Avgoustakis K, Beletsi A, Panagi Z et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int. J. Pharm. 259(1-2), 115-127 (2003). (Pubitemid 36638559)
20. Beletsi A, Panagi Z, Avgoustakis K. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int. J. Pharm. 298(1), 233-241 (2005). (Pubitemid 40828344)
21. Kocbek P, Teskac K, Brozic P, Laninik Riner T, Gobec S, Kristl J. Effect of free and in poly(e-caprolactone) nanoparticles incorporated new type 1 17b-hydroxysteroid dehydrogenase inhibitors on cancer cells. Curr. Nanosci. 6(1), 69-76 (2010).
22. Welgus HG, Connolly NL, Senior RM. 12-o-tetradecanoyl-phorbol-13-acetate- differentiated U937 cells express a macrophage-like profle of neutral proteinases. High levels of secreted collagenase and collagenase inhibitor accompany low levels of intracellular elastase and cathepsin G. J. Clin. Invest. 77(5), 1675-1681 (1986). (Pubitemid 16047114)
23. Segat D, Tavano R, Donini M et al. Proinfammatory effects of bare and PEGylated ORMOSIL-, PLGA-and SUV-NPs on monocytes and PMNs and their modulation by f-MLP. Nanomedicine (Lond). 6(6), 1027-1046 (2011).
24. Compagnin C, Baù L, Mognato M et al. The cellular uptake of meta-tetra(hydroxyphenyl)chlorin entrapped in organically modifed silica nanoparticles is mediated by serum proteins. Nanotechnology 20(34), 345101 (2009).
25. Konan YN, Chevallier J, Gurny R, Allémann E. Encapsulation of p-THPP into nanoparticles: cellular uptake, subcellular localization and effect of serum on photodynamic activity. Photochem. Photobiol. 77(6), 638-644 (2003).
26. Maeda H, Wu J, Sawa Y, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J. Control Release 65(1-2), 271-284 (2000). (Pubitemid 30122932)
27. Bezdetnaya L, Zeghari N, Belitchenko I et al. Spectroscopic and biological testing of photobleaching of porphyrins in solutions. Photochem. Photobiol. 64(2), 382-386 (1996). (Pubitemid 26351268)
28. Vargas A, Lange N, Arvinte T, Cerny R, Gurny R, Delie F. Toward the understanding of the photodynamic activity of m-THPP encapsulated in PLGA nanoparticles: correlation between nanoparticle properties and in vivo activity. J. Drug Target 17(8), 599-609 (2009).
29. Lassalle HP, Dumas D, Gräfe S, D'Hallewin MA, Guillemin F, Bezdetnaya L. Correlation between in vivo pharmacokinetics, intratumoral distribution and photodynamic effciency of liposomal temoporfn. J. Control Release 34(2), 118-124 (2009).
30. Preuss A, Chen K, Hackbarth S, Wacker M, Langer K, Röder B. Photosensitizer loaded HSA nanoparticles II: in vitro investigations. Int. J. Pharm. 404(1-2), 308-316 (2011).
31. Hopkinson HJ, Vernon DI, Brown SB. Identifcation and partial characterization of an unusual distribution of the photosensitizer meta-tetrahydroxyphenyl chlorin (temoporfn) in human plasma. Photochem. Photobiol. 69(4), 482-488 (1999). (Pubitemid 129555312)
32. Sasnouski S, Zorin V, Khludeyev I, D'Hallewin MA, Guillemin F, Bezdetnaya L. Investigation of Foscan interactions with plasma proteins. Biochim. Biophys. Acta 1725(3), 394-402 (2005). (Pubitemid 41393535)
33. Moor AC. Signaling pathways in cell death and survival after photodynamic therapy. J. Photochem. Photobiol. B. 57(1), 1-13 (2000).
34. Teiten MH, Bezdetnaya L, Morlière P, Santus R, Guillemin F. Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan localisation in cultured tumour cells. Br. J. Cancer 88(1), 146-152 (2003). (Pubitemid 36241232)
35. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16(10), 1217-1226 (2002). (Pubitemid 34815409)
36. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. Improved cellular uptake of chitosan-modifed PLGA nanospheres by A549 cells. Int. J. Pharm. 382(1-2), 198-204 (2009).
37. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 17(2), 93-102 (1996). (Pubitemid 26031365)
38. Cegnar M, Premzl A, Zavasnik-Bergant V, Kristl J, Kos J. Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp. Cell Res. 301(2), 223-231 (2004). (Pubitemid 39504975)
39. Berlanda J, Kiesslich T, Engelhardt V, Krammer B, Plaetzer K. Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. J. Photochem. Photobiol. B. 100(3), 173-180 (2010).
40. Konan YN, Berton M, Gurny R, Allémann E. Enhanced photodynamic activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur. J. Pharm. Sci. 18(3-4), 241-249 (2003). (Pubitemid 36349275)